





ARTIC PC Adverse Event/Serious Adverse Event reporting SOP

V 1

Role	Name	Signature	Date
SOP author	Kim Harman		15 JULY 2016
SOP review	Paul Little		15/7/16
SOP review	Curt Brugman		16-9-16
CTU approval	Erwin van Geenen FRANK LEHS		16-9-16

Effective Date	16 Sept 16	Review Date	15 Sept 17
----------------	------------	-------------	------------

Revision History

Version	Revision	Date
1	New document	

Definitions and abbreviations

Centre	The University department supporting recruitment to the trial. In this trial the lead Centre is the University of Southampton and the specific department is Aldermoor Health Centre. The coordinating Centres are the Universities of Bristol, Oxford and Cardiff.
CCF	Coordinating Centre File, a file similar to the TMF held by the centres supporting the trial which holds all the information relevant to that centre.
CI	Chief Investigator, is in overall charge of the project.
CRF	Case Report Form, the form that collects all the

CONFIDENTIAL: UNAUTHORISED COPYING PROHIBITED

	data about participants.
CTA	Clinical Trials Authority
CTIMP	Controlled Trial of an Investigational Medicinal Product.
CTU	Clinical Trials Unit, a supporting unit often within a University.
DL	Development Lead (SOP); anyone with previous experience of the procedure / completing the procedure being described, who will take the lead in drafting the SOP or delegating specific section of the SOP to the appropriate person.
DG	Development Group (SOP); A group of approximately 2-4 personnel who are responsible for helping develop, maintain and improve the SOP system, consists of other suitably experienced members.
DM	Data Manager, an individual with responsibility for ensuring data is captured in an ethical manner and a useable format.
GCP	Good Clinical Practice, the regulations that govern the practice of researchers.
GMP	Good Manufacturing Practice, of IMP.
IMP	Investigational Medicinal Product
ISF	Investigator Site File, a file held by a Local Investigator containing all information they need to safely conduct the project.
LI	Local Investigator, the individual with responsibility for the conduct of the study at their site. In a CTIMP this has to be a medically qualified doctor or pharmacist.
MHRA	Medicines Healthcare Regulatory Authority
PI	Principal Investigator, an Individual responsible for the safe and ethically conduct of the study, often leading a centre in academic research.
S(T)A	Study (Trial) Administrator a member of staff from the Centre.
S(T)C	Study (Trial) coordinator a senior member of staff who may have delegated tasks
S(T)M	Study (Trial Manager) a senior member of staff from the Centre who will have delegated tasks to run the project.
SOP	Standard Operating Procedure, specifies what should be done, when, where and by whom
Site	Primary care Centre that recruits into the study or trial
Sponsor	The University of Southampton

CONFIDENTIAL: UNAUTHORISED COPYING PROHIBITED

TMF	Trial Master File, a file containing all relevant information about the running of the project.
-----	---

Contents

Revision History1

Definitions and abbreviations1

1. INTRODUCTION3

2. DEFINITIONS4

2.1 Adverse Reaction (AR)4

2.2 Adverse Event (AE)4

2.3 Serious Adverse Event (SAE).....4

2.4 CTIMP5

2.5 MHRA.....5

2.6 Main REC5

2.7 Sponsor.....5

2.7 Research Governance Office5

2.8 Clinical Trials Unit5

3. SCOPE5

4. RESPONSIBILITIES5

4.1.....6

4.2.....6

4.3.....6

5. PROCEDURE.....6

6. RELATED DOCUMENTS7

1. INTRODUCTION

ARTIC PC is an observational study, with a nested RCT within. It is known that trials among adults suggest modest benefit even among important clinical subgroups of this project, we are aware of no randomised placebo-controlled trials available to either support or dispute the common use of antibiotics in children with chest infections. A national research priority is to do clinical trials of medicines in children to ensure children are better represented in RCTs and that medicines for children are more evidence based. Because of the lack of evidence in children it is difficult for GPs to go against the rising tide of antibiotic use to reduce prescribing antibiotics for children. It may be that antibiotics in children also have limited benefit, however the differences in immunity and

CONFIDENTIAL: UNAUTHORISED COPYING PROHIBITED

anatomy between adults and children prohibit simply applying evidence derived in adults to the management of children. If any reduction in antibiotic prescribing is to be achieved, one of the key issue for patients and clinicians is the difficulty of knowing whether the child presenting is an 'average' child: as with adults there is likely to be variation in pathophysiology and disease severity among children with acute cough.

However, we think that a trial simply powered to estimate the average effect of antibiotics would provide unconvincing evidence to persuade GPs not to prescribe, as GPs tend to prescribe in the face of uncertainty, giving patients the 'benefit of the doubt, and continue prescribing to particular subgroups according to their own ad hoc criteria. Thus it is necessary to study the heterogeneity of these children with acute cough and explore whether clinical and pathophysiological determinants identify subgroups where antibiotic treatment is or is not effective.

This is a randomised placebo controlled parallel group trial of amoxicillin or placebo for children presenting with chest infections in primary care. The trial is nested within an observational study where the same measures and outcomes will be collected.

The AE and SAEs we are interested in are not the common known illness presentations and side effects of antibiotics e.g. rash, diarrhoea but major reactions including, but not exclusively, reactions to the antibiotics such as anaphylaxis, severe allergy requiring steroid administration, emergency hospitalization for chest problems and severe Clostridium (antibiotic related diarrhoea).

2. DEFINITIONS

2.1 Adverse Reaction (AR)

In a CTIMP, any untoward and unintended response in a participant to an IMP which is related to any dose administered to that subject.

2.2 Adverse Event (AE)

Any untoward medical occurrence in a participant taking part in health care research that does not necessarily have a causal relationship with the research.

The following do not need to be reported as AEs if they are recorded as medical history/concomitant illness on the CRF at baseline.

Planned procedure, unless the condition for which the procedure was planned has worsened from the point of signing the consent form and appears to be related to the research.

Pre existing conditions found as a result of screening procedures.

2.3 Serious Adverse Event (SAE)

Any adverse event/adverse reaction or unexpected adverse reaction that:

Results in death

CONFIDENTIAL: UNAUTHORISED COPYING PROHIBITED

Is life threatening

Requires in patient hospitalisation (defined as over 4 hours)

Results in persistent or significant disability/incapacity

Is a congenital anomaly or birth defect.

2.4 CTIMP

Clinical Trial of an Investigational Medical Product. Any investigation in human subjects, other than a non interventional trial, intended:

to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal products;

to identify any adverse reactions to one or more such products;

to study absorption, distribution, metabolism and excretion of one or more such products with the object of ascertaining the safety or efficacy of those products.

2.5 MHRA

Medicines and Healthcare Products Regulatory Agency. MHRA (Medicines) is the competent authority for the UK in relation to the EU Directive and the Clinical Trials Regulations. MHRA (Devices) is the competent authority for the UK in relation to the Medical Devices Regulations 2002.

2.6 Main REC

The Research Ethics Committee undertaking the ethical review of the application.

2.7 Sponsor

The University of Southampton as an institution takes responsibility for the initiation and management of this Research Study.

2.7 Research Governance Office

The office at the University of Southampton (UoS) tasked with ensuring that all Research Studies undertaken by members of UoS, or in its name, or sponsored by UoS are conducted in accordance with applicable legislation, guidelines and local policies.

2.8 Clinical Trials Unit

The Clinical Trials Unit at the Julius Centre for Health sciences and Primary care of the University Medical Centre, Utrecht will be responsible for the data management and ensuring quality through working with the Department of Biostatistics and Research Support.

3. SCOPE

This SOP is for use in the reporting of SAEs for the ARTIC PC study and trial only. It is not intended to replace clinical care that is deemed appropriate for the individual.

4. RESPONSIBILITIES

CONFIDENTIAL: UNAUTHORISED COPYING PROHIBITED

4.1 Each PI at site is responsible for completing the ARTIC PC Study SAE form when any SAE is found. This should be completed fully and returned by fax to the ARTIC PC Study team on 023 XX XXXX within 24 hours of becoming aware of the event. It is also possible to report the SAE using the Research Online system available.

4.2 The causality and expectedness will be re-assessed by the trial team of Professor Paul Little or in his absence Professor Michael Moore. This may be delegated to the local Principle Investigators in the supporting University Centres (Bristol, Cardiff and Oxford).

4.3 Also the guidelines for SAE and safety reporting to the regulatory authorities and Ethical Committees should be followed. To support this we will send out an overview of all SAEs that occurred every 12 months to all centres. It will be the responsibility of the lead centre (University of Southampton) to inform the authorities and ethical committees involved. In general they like to receive a yearly update, but it could be there are local differences between the centres.

5. PROCEDURE

Legislation requires that SAEs be reported to the appropriate authorities in a timely manner. All Serious Adverse Events should be immediately reported to the following (timelines are given):

All SAEs occurring during the study should be reported on a specific form on the ARTIC PC website within 24 hours. The SAE form is available for all patients included in the study as one of the surveys on the ARTIC PC online system (named Research Online (RO)), and (depending on the organisation) also as a paper form.

The GP will fill in the ARTIC PC SAE form as soon as he/she becomes aware a SAE occurred. This form will be faxed to the coordinating centre as soon as possible, who will immediately fill in the SAE form of the patient involved on the ARTIC PC website*. To make sure the Study manager is aware that a SAE occurred and that the related data is entered on the website, the GP should inform the Study team by telephone as well. Alternatively the GP can fill in the SAE form on the website directly. SAEs that occur during the study must also be documented in the subject's medical record. On completion of an SAE on the ARTIC PC website, an automatic email is generated to alert the trial management team. The Chief or Principal Investigator, on behalf of the sponsor, will assess whether the SAE is a SUSAR (Suspected Unexpected Serious Adverse Reaction).

A SUSAR is any adverse reaction that is classed as serious and is suspected to be caused by the investigational medicinal product (IMP) and is not consistent with the information about the (IMP) in the Summary of Product Characteristics (SmPC). The IMP used for this study is the well-known antibiotic amoxicillin, it is being used within its licence therefore SUSARs are not expected.

CONFIDENTIAL: UNAUTHORISED COPYING PROHIBITED

If the CI/PI (on behalf of the sponsor) decides the SAE should be classified as a SUSAR, all medically qualified co-Investigators will be informed immediately and delegated, by the sponsor, to report the SUSAR to their competent authority (CA) and ethics committee (EC). SUSARs should only be entered into EudraVigilance CT. For a SUSAR which is fatal or life threatening, the Chief Investigator, on behalf of the sponsor, has 7 days after the reporting GP becoming aware of the event to report the SUSAR to the CA and to the EC. For a SUSAR which is not fatal or life threatening, the Chief Investigator, on behalf of the sponsor, has 15 days to report this event to the CA and to the EC. The SUSAR is recorded in the participants' medical notes and the participant is followed up. All SUSAR's should be included in the annual safety report.

****For how to fill in a SAE form on the website see the Manual for the ARTIC PC Online System ****

1- days. However, in the case of a 3rd SAE the sponsor should be informed immediately by faxing a completed ARTIC PC SAE report to the following number:

It could be that during assessment of the reported SAEs, additional information is requested. If so, it should be provided in a timely fashion to ensure accurate follow-up of each case.

The Table 1 Timelines and responsibilities in SAEs page 9 describes the timelines and responsibilities.

6. RELATED DOCUMENTS

The ARTIC PC Signature and delegation log will support the completion of AE/SAE reporting.

The ARTIC PC IMP handling document describes the handling of the IMP, the training and delegation logs indicate the site personnel who are deemed responsible for completing the SAE reporting mechanism. The ARTIC PC IMP handling SOP describes the procedures for IMP handling through the whole trial processes.

The ARTIC PC Unblinding SOP describes the processes required for unblinding a participant.

Table 1 Timelines and responsibilities in SAEs

What	Who	When	How	To whom
SAE	CI or Sponsor	Within 24 hours of the staff becoming aware of the event	SAE report form for project	Main REC
Urgent safety measures	CI or Sponsor	immediately	By telephone or by notice in writing setting out the reasons and the plan for further action	Main REC, local REC if by PI
SUSARs	CI or Sponsor	Within 7 days	In writing	MHRA
Progress reports	Sponsor or Sponsor's legal representative, always signed by CI	Annually (starting 12/12 after the favourable opinion)	From HRA website	Main REC
Declaration of the conclusion or early termination of the research	CI or Sponsor	Within 90 days (conclusion) within 15 days (early termination) NB the end should be defined in the Protocol	From HRA website	Main REC
Summary of final report	CI or Sponsor	Within one year of the conclusion of the research	No standard format. The summary should include information on whether the project achieved its	Main REC

CONFIDENTIAL: UNAUTHORISED COPYING PROHIBITED

		objectives, the main findings and arrangements for publication and dissemination to participants.	
--	--	---	--